1Physics and Astronomy, University of British Columbia, Vancouver, BC, Canada; 2Radiation Biology, BC Cancer Research Institute, Vancouver, BC, Canada; 3RF Therapeutics, Vancouver, BC, Canada
We validate an MR-visible, necrosis-avid contrast agent(RF1101) using TUNEL staining and DCEMRI. The agent is injected and binds to areas of apoptosis/necrosis and unbound agent is excreted from the systemic circulation. T1-weighted imaging is performed after approximately 24h to identify areas of contrast agent uptake. Data from a preclinical cancer model is shown with spectacular agreement between histologically identified areas of necrosis and RF1106 uptake.